Mankind Pharma Ltd
NSE:MANKIND
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 853.1
2 792.55
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Mankind Pharma Ltd
Net Income (Common)
Mankind Pharma Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Net Income (Common)
₹19.1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Net Income (Common)
₹55.7B
|
CAGR 3-Years
47%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Net Income (Common)
₹44.8B
|
CAGR 3-Years
20%
|
CAGR 5-Years
22%
|
CAGR 10-Years
15%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Net Income (Common)
₹110.5B
|
CAGR 3-Years
21%
|
CAGR 5-Years
21%
|
CAGR 10-Years
6%
|
|
|
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
Net Income (Common)
₹41.9B
|
CAGR 3-Years
23%
|
CAGR 5-Years
20%
|
CAGR 10-Years
17%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Net Income (Common)
₹18B
|
CAGR 3-Years
12%
|
CAGR 5-Years
27%
|
CAGR 10-Years
8%
|
|
Mankind Pharma Ltd
Glance View
Mankind Pharma Ltd. stands out as one of India's leading pharmaceutical companies, renowned for its commitment to developing and delivering affordable healthcare solutions. Founded in 1991, Mankind has carved a niche in the industry by focusing on high-quality generic medicines, over-the-counter (OTC) products, and niche therapeutics. With an impressive portfolio of over 800 products spanning various therapeutic segments, including cardiology, gynecology, dermatology, and antibiotics, the company has been instrumental in improving access to medications across the country. Mankind's innovative approach to drug development and its robust research and development capabilities support its strategy of launching products that fill critical gaps in the market. As an investor, Mankind Pharma presents a compelling opportunity due to its impressive growth trajectory and strategic expansion plans. The company has embraced a strong distribution network that not only reaches urban centers but also penetrates rural markets, enhancing its sales potential. Recently, Mankind has been making waves with its ambitious plans for international expansion, eyeing markets in Asia and Africa to leverage its production capabilities and widen its global footprint. With strong financial performance demonstrated through consistent revenue growth, coupled with a commitment to corporate governance and sustainable practices, Mankind Pharma is poised for long-term success, making it an enticing prospect for those looking to invest in the burgeoning pharmaceutical sector.
See Also
What is Mankind Pharma Ltd's Net Income (Common)?
Net Income (Common)
19.1B
INR
Based on the financial report for Mar 31, 2024, Mankind Pharma Ltd's Net Income (Common) amounts to 19.1B INR.
What is Mankind Pharma Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
15%
Over the last year, the Net Income (Common) growth was 49%. The average annual Net Income (Common) growth rates for Mankind Pharma Ltd have been 15% over the past three years .
You don't have any saved screeners yet
